Autek China Inc
SZSE:300595

Watchlist Manager
Autek China Inc Logo
Autek China Inc
SZSE:300595
Watchlist
Price: 14.3 CNY 0.56% Market Closed
Market Cap: ¥12.8B

EV/EBITDA

15.4
Current
24%
Cheaper
vs 3-y average of 20.3

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.4
=
Enterprise Value
¥9.3B
/
EBITDA
¥634.5m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
15.4
=
Enterprise Value
¥9.3B
/
EBITDA
¥634.5m

Valuation Scenarios

Autek China Inc is trading below its 3-year average

If EV/EBITDA returns to its 3-Year Average (20.3), the stock would be worth ¥18.83 (32% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+87%
Average Upside
68%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 15.4 ¥14.3
0%
3-Year Average 20.3 ¥18.83
+32%
5-Year Average 28.2 ¥26.17
+83%
Industry Average 26.2 ¥24.32
+70%
Country Average 28.8 ¥26.75
+87%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
¥9.3B
/
Jan 2026
¥634.5m
=
15.4
Current
¥9.3B
/
Dec 2026
¥952.7m
=
9.8
Forward
¥9.3B
/
Dec 2027
¥1B
=
9.2
Forward
¥9.3B
/
Dec 2028
¥997.9m
=
9.3
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
CN
Autek China Inc
SZSE:300595
12.8B CNY 15.4 26.7
US
Medline Inc
NASDAQ:MDLN
58.8B USD 0 0
JP
Hoya Corp
TSE:7741
9.7T JPY 28 38.6
CH
Alcon AG
SIX:ALC
29.2B CHF 14.4 37.3
DK
Coloplast A/S
CSE:COLO B
94.7B DKK 12.5 23.5
US
Align Technology Inc
NASDAQ:ALGN
13.5B USD 14.3 33
UK
ConvaTec Group PLC
LSE:CTEC
4.3B GBP 11.5 32.7
CA
Bausch + Lomb Corp
NYSE:BLCO
5.6B USD 16.8 -15.5
JP
Asahi Intecc Co Ltd
TSE:7747
890.2B JPY 23.8 50.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
36.7B CNY 20.9 23.3
KR
HLB Inc
KOSDAQ:028300
8T KRW -80.8 -36.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Autek China Inc
SZSE:300595
Average EV/EBITDA: 17.5
15.4
16%
1
US
M
Medline Inc
NASDAQ:MDLN
Not Available
9%
N/A
JP
Hoya Corp
TSE:7741
28
13%
2.2
CH
Alcon AG
SIX:ALC
14.4
9%
1.6
DK
Coloplast A/S
CSE:COLO B
12.5
6%
2.1
US
Align Technology Inc
NASDAQ:ALGN
14.3
14%
1
UK
ConvaTec Group PLC
LSE:CTEC
11.5
11%
1
CA
Bausch + Lomb Corp
NYSE:BLCO
16.8
29%
0.6
JP
A
Asahi Intecc Co Ltd
TSE:7747
23.8
13%
1.8
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
20.9
13%
1.6
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -80.8 N/A N/A
P/E Multiple
Earnings Growth PEG
CN
Autek China Inc
SZSE:300595
Average P/E: 33.2
26.7
12%
2.2
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
JP
Hoya Corp
TSE:7741
38.6
15%
2.6
CH
Alcon AG
SIX:ALC
37.3
32%
1.2
DK
Coloplast A/S
CSE:COLO B
23.5
21%
1.1
US
Align Technology Inc
NASDAQ:ALGN
33
34%
1
UK
ConvaTec Group PLC
LSE:CTEC
32.7
41%
0.8
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -15.5 N/A N/A
JP
A
Asahi Intecc Co Ltd
TSE:7747
50.3
40%
1.3
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
23.3
9%
2.6
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.2 N/A N/A

Market Distribution

Lower than 72% of companies in China
Percentile
28th
Based on 5 409 companies
28th percentile
15.4
Low
0 — 16.3
Typical Range
16.3 — 53.1
High
53.1 —
Distribution Statistics
China
Min 0
30th Percentile 16.3
Median 28.8
70th Percentile 53.1
Max 49 021

Autek China Inc
Glance View

Market Cap
12.8B CNY
Industry
Health Care

Autek China Inc. stands as an emblematic figure in the dynamic landscape of medical devices and biotechnology in China. Rooted in its mission to innovate within the realms of diagnostic imaging and therapeutic ultrasound equipment, the company has maneuvered through this niche market by leveraging both cutting-edge technology and strategic partnerships. Autek's portfolio includes a range of high-quality ultrasound machines and imaging solutions that cater to the rapidly evolving needs of hospitals and clinics. By capitalizing on the growing demand for advanced healthcare services in China, Autek has tailored its product offerings to resonate with local market needs while maintaining competitive pricing strategies. This keen understanding of market dynamics allows Autek to maintain a robust sales pipeline and forge sturdy relationships within the medical community, driving its revenue growth engine. The company's operational blueprint hinges on an impressive blend of research-driven innovation and effective distribution networks. Autek continually invests in research and development, aspiring to push technological boundaries and uphold its reputation as a pioneer in the medical imaging sector. This investment lays the groundwork for creating state-of-the-art products that are not only technologically advanced but also user-friendly for medical professionals. Autek's adeptness at navigating regulatory landscapes ensures smooth market entry and expansion for its offerings. Furthermore, its strategic alliances with healthcare providers and government entities enhance its distribution network, ensuring that its products reach a wide spectrum of healthcare institutions across China. Autek makes its money by selling its technologically advanced and reliable devices, as well as providing ongoing support and maintenance services, forming the backbone of its revenue model and securing its position in the competitive arena.

Intrinsic Value
14.45 CNY
Undervaluation 1%
Intrinsic Value
Price ¥14.3
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett